Nautilus, a Seattle, US-based biotechnology firm co-founded in 2016 by Parag Mallick and Sujal Patel, has reportedly announced that it is developing a new medical device that will enable a comprehensive analysis of the trillions of proteins that exist in the human body.
According to the company, existing medical instruments can only measure up to 8% of the different kinds of proteins in blood samples. The new device, however, would be able to count and identify 95% of the proteins present in a biological sample, a level of detail that has never been achieved before.
Nautilus claims, such protein measures, which are unique to each individual and vary over time, would not only aid doctors in identifying more particular types of disease, but also pharmaceutical firms in developing more accurate medications with fewer adverse effects.
Patel stated that all of these factors together will transform the overall healthcare landscape for the better, and also usher in a new era of medicine in the coming decades.
In June, the firm went public via a merger deal with existing public firm, Arya Sciences, getting access to an additional $345 million in funding. The firm now employs over 100 people, who are split between its Seattle and Bay Area offices, with a market cap of approximately $1 billion.
Around 20,000 distinct kinds of proteins are found in human cells, and they are responsible for vital processes such as digestion and disease prevention.
Each cell in the body contains different amounts of each protein. The issue is that scientists do not possess the means to measure how much of each type of protein a cell contains since current instruments are costly, inefficient, and only measure a percentage of all proteins.
Nautilus is tackling this issue through its new system. The company’s ultimate objective is to provide a "proteome," or a comprehensive profile of the levels of each protein in blood or tissue samples from different organs in the human body.